NCT03672266

Brief Summary

The goal of this study is to characterize biophysiolgoical signals as a comprehensive profile of the nervous systems in order to understand interactions between the brain and body, while an individual performs naturalistic behaviors (ex. walking, pointing) and while breathing at a slow controlled pace. The investigators aim to study these interactions among a variety of populations, from healthy individuals to those with disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD (Attention-deficit/hyperactivity disorder) diagnosis, Asperger's Syndrome, Alzheimer's Disease, and/or Fragile X syndrome

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 7, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 14, 2018

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
24 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 25, 2025

Completed
Last Updated

April 29, 2026

Status Verified

October 1, 2025

Enrollment Period

7.3 years

First QC Date

September 7, 2018

Last Update Submit

April 23, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Unitless Stochastic Signatures of Biophysiological Signals, consisting of the Empirically Estimated Shape and Dispersion (scale) Parameters of Probability Distribution Functions

    Biophysical signals extracted from the brain and heart (mV) and motor kinematics (m/s) activities will be normalized and scaled to a unit-less waveform dataset. The standardized unitless data set will account for anatomical differences and will then be empirically characterized as families of probability distributions for each person, by the shape and scale parameters of continuous families of probability distribution functions with variable shapes and dispersion (noise to signal ratio). These parameters are objective biomarkers for a variety of disorders, and inform the level of noise-to-signal ratio and predictability of an individual's biorhythms (Torres, 2018). Torres, E. (2018). Objective Biometric Methods for the Diagnosis and Treatment of Nervous Systems Disorder: Elsevier

    through study completion, an average of 1 year

Secondary Outcomes (2)

  • Brain and Body Connectivity metrics and Derived Geometric and Topological Indexes from the Network Connectivity Model and Inverse Kinematic Model

    through study completion, an average of 1 year

  • Information theoretic metric

    through study completion, an average of 1 year

Study Arms (2)

Neurological Disorder

Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia

Neurotypical

Healthy individuals with no known neurological disorders

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

No restriction from which the cohort will be selected

You may qualify if:

  • Clinical diagnosis of any one of the following:
  • Autism Spectrum Disorder(s)
  • ADHD
  • Asperger's syndrome
  • Alzheimer's disease
  • Fragile X syndrome
  • Parkinson's disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rutgers University

Piscataway, New Jersey, 08854-8020, United States

Location

MeSH Terms

Conditions

Child Development Disorders, PervasiveAttention Deficit Disorder with HyperactivityAsperger SyndromeAlzheimer DiseaseEssential TremorLewy Body Disease

Condition Hierarchy (Ancestors)

Neurodevelopmental DisordersMental DisordersAttention Deficit and Disruptive Behavior DisordersAutism Spectrum DisorderDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMovement DisordersParkinsonian DisordersBasal Ganglia DiseasesSynucleinopathies

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 7, 2018

First Posted

September 14, 2018

Study Start

August 1, 2018

Primary Completion

December 1, 2025

Study Completion

December 25, 2025

Last Updated

April 29, 2026

Record last verified: 2025-10

Locations